A- A A+

How the Suboxone Education Programme presented as a solution to risks in the Canadian opioid crisis: a critical discourse analysis. 

Sud A, Strang M, Buchman DZ, Spithoff S, Upshur REG, Webster F, Grundy Q. 

BMJ Open. 2022 Jul 12;12(7):e059561. doi: 10.1136/bmjopen-2021-059561. PMID: 35820738; PMCID: PMC9277368.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277368/

Outpatient Microdose Induction with Transdermal Buprenorphine: A Case Series. 

Menard S, Jhawar A. 

Healthcare (Basel). 2022 Jul 14;10(7):1307. doi: 10.3390/healthcare10071307. PMID: 35885833; PMCID: PMC9317019.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317019/

The Naloxone Component of Buprenorphine/Naloxone: Discouraging Misuse, but at What Cost? 

Gregg J, Hartley J, Lawrence D, Risser A, Blazes C. 

J Addict Med. 2022 Aug 1. doi: 10.1097/ADM.0000000000001030. Epub ahead of print. PMID: 35913990.

Abstract

https://journals.lww.com/journaladdictionmedicine/Abstract/9900/The_Naloxone_Component_of_Buprenorphine_Naloxone_.28.aspx

Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.

Sadek J, Saunders J. 

BMC Psychiatry. 2022 Jul 30;22(1):516. doi: 10.1186/s12888-022-04175-9. PMID: 35908052; PMCID: PMC9338516.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338516/

Development of an intravenous low-dose buprenorphine initiation protocol. 

Jablonski LA, Bodnar AR, Stewart RW. 

Drug Alcohol Depend. 2022 Aug 1;237:109541. doi: 10.1016/j.drugalcdep.2022.109541. Epub 2022 Jun 20. PMID: 35753281.

Abstract

https://www.sciencedirect.com/science/article/abs/pii/S0376871622002782

Depot buprenorphine: Safe and effective for clients in jails and prisons?

There are barriers to receiving opioid use disorder medications, such as buprenorphine, for individuals in criminal justice settings like jails and prisons. These include limited resources to ensure adequate medical monitoring and the potential for their illegal sharing or selling (i.e., diversion) to other inmates. This study examined safety and opioid use outcomes in a group of incarcerated individuals who received a longer acting, injection formulation of buprenorphine. (Recovery Research Institute, USA, Juli 2022)

https://www.recoveryanswers.org/research-post/depot-buprenorphine-safe-effective-clients-jails-prisons/

Treatment Choices: Buprenorphine

Exchange Supplies, UK. Third edition. oD

https://www.exchangesupplies.org/pdf/P802.pdf

Treatment Choices: Suboxone

Exchange Supplies, UK. Third edition. oD

https://www.exchangesupplies.org/pdf/P805.pdf

A Review of Novel Methods To Support The Transition From Methadone and Other Full Agonist Opioids To Buprenorphine/Naloxone Sublingual In Both Community and Acute Care Settings,

Ghosh, Sumantra Monty MD, MSc, FRCPC, ISAM1; Klaire, Sukhpreet MD, CCFP2; Tanguay, Robert MD, FRCPC, ISAM3; Manek, Mandy MD, CCFP4; Azar, Pouya MD, FRCPC, ISAM5

The Canadian Journal of Addiction: December 2019 - Volume 10 - Issue 4 - p 41-50, doi: 10.1097/CXA.0000000000000072

https://journals.lww.com/cja/fulltext/2019/12000/a_review_of_novel_methods_to_support_the.7.aspx

The Association between Buprenorphine Treatment Duration and Mortality: A Multi-site Cohort Study of People who Discontinued Treatment. 

Glanz JM, Binswanger IA, Clarke CL, Nguyen AP, Ford MA, Ray GT, Xu S, Hechter RC, Yarborough BJH, Roblin DW, Ahmedani B, Boscarino JA, Andrade SE, Rosa CL, Campbell CI. 

Addiction. 2022 Jul 11. doi: 10.1111/add.15998. Epub ahead of print. PMID: 35815386.

https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.15998

Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial. 

Jutras-Aswad D, Le Foll B, Ahamad K, Lim R, Bruneau J, Fischer B, Rehm J, Wild TC, Wood E, Brissette S, Gagnon L, Fikowski J, Ledjiar O, Masse B, Socias ME; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. 

Am J Psychiatry. 2022 Jun 15:appiajp21090964. doi: 10.1176/appi.ajp.21090964. Epub ahead of print. PMID: 35702828.

https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.21090964

Trends and Disparities in Access to Buprenorphine Treatment Following an Opioid-Related Emergency Department Visit Among an Insured Cohort, 2014-2020. 

Stevens MA, Tsai J, Savitz ST, Nath B, Melnick ER, D'Onofrio G, Jeffery MM. 

JAMA Netw Open. 2022 Jun 1;5(6):e2215287. doi: 10.1001/jamanetworkopen.2022.15287. PMID: 35657629.

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2792963

Identifying and Characterizing Medical Advice-Seekers on a Social Media Forum for Buprenorphine Use. 

Garcia GP, Dehghanpoor R, Stringfellow EJ, Gupta M, Rochelle J, Mason E, Pujol TA, Jalali MS. 

Int J Environ Res Public Health. 2022 May 22;19(10):6281. doi: 10.3390/ijerph19106281. PMID: 35627818; PMCID: PMC9141384.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9141384/

Patient perspectives on depot buprenorphine treatment for opioid addiction - a qualitative interview study. 

Johnson B, Flensburg OL, Capusan AJ. 

Subst Abuse Treat Prev Policy. 2022 May 25;17(1):40. doi: 10.1186/s13011-022-00474-2. PMID: 35614466; PMCID: PMC9131643.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131643/

Retention rates with monthly depot buprenorphine in general practice in Melbourne, Australia. 

Andrada E, Rodriguez M, Bandalan JH, Dangelo-Kemp D, Johnston L, Wilson H. 

Aust J Gen Pract. 2022 Jun;51(6):447-451. doi: 10.31128/AJGP-07-21-6098. PMID: 35637592.

https://www1.racgp.org.au/ajgp/2022/june/retention-rates-with-monthly-depot-buprenorphine

Association Between Receipt of Antidepressants and Retention in Buprenorphine Treatment for Opioid Use Disorder: A Population-Based Retrospective Cohort Study. 

Zhang K, Jones CM, Compton WM, Guy GP, Evans ME, Volkow ND. 

J Clin Psychiatry. 2022 Apr 27;83(3):21m14001. doi: 10.4088/JCP.21m14001. PMID: 35485928.

Abstract

https://pubmed.ncbi.nlm.nih.gov/35485928/

Effects of Buprenorphine Dose and Therapeutic Engagement on Illicit Opiate Use in Opioid Use Disorder Treatment Trials. 

Bergen AW, Baurley JW, Ervin CM, McMahan CS, Bible J, Stafford RS, Mudumbai SC, Saxon AJ. 

International Journal of Environmental Research and Public Health. 2022; 19(7):4106. doi.org/10.3390/ijerph19074106 

https://www.mdpi.com/1660-4601/19/7/4106/htm

Prehospital Buprenorphine Treatment for Opioid Use Disorder by Paramedics: First Year Results of the EMS Buprenorphine Use Pilot,

H. Gene Hern, Vanessa Lara, David Goldstein, M. Kalmin, S. Kidane, S. Shoptaw, Ori Tzvieli & Andrew A. Herring (2022)

Prehospital Emergency Care, DOI: 10.1080/10903127.2022.2061661

https://www.tandfonline.com/doi/full/10.1080/10903127.2022.2061661

Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use. 

Xu KY, Mintz CM, Presnall N, Bierut LJ, Grucza RA. 

JAMA Netw Open. 2022;5(5):e2211363. doi:10.1001/jamanetworkopen.2022.11363

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2792121

Six-month buprenorphine-naloxone treatment is associated with neurocognitive function improvement in opioid dependence. 

Ghosh A, Mahintamani T, Rana DK, Basu D, Mattoo SK. 

Indian J Psychiatry. 2022 Mar-Apr;64(2):199-208. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_792_21. Epub 2022 Mar 24. PMID: 35494328; PMCID: PMC9045353.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045353/

Non–prescribed buprenorphine preceding treatment intake and clinical outcomes for opioid use disorder

Williams, Arthur Robin et al.

Journal of Substance Abuse Treatment, Volume 0, Issue 0, 108770 

https://www.journalofsubstanceabusetreatment.com/article/S0740-5472(22)00052-6/fulltext

Buprenorphine for High-dose Tramadol Dependence: A Case Report of Successful Outpatient Treatment. 

Mukau L, Wormley K, Tomaszewski C, Ahmad B, Vohra R, Herring AA. 

Clin Pract Cases Emerg Med. 2022 Feb;6(1):71-74. doi: 10.5811/cpcem.2021.12.54602. PMID: 35226854; PMCID: PMC8885221.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885221/

Integrating Buprenorphine Treatment for Opioid Use with Primary Care is Associated with Greater Retention in Treatment. 

Mirer AG, Tiemstra JD, Hammes NE, Cloum HM, LaFavor KJ. 

J Am Board Fam Med. 2022 Jan-Feb;35(1):206-208. doi: 10.3122/jabfm.2022.01.210292. PMID: 35039431.

https://www.jabfm.org/content/35/1/206.long

Experiences and Preferences of Opioid-Use-Disorder Patients Who Switched from Brand to Generic Buprenorphine/Naloxone Films: A Case Series. 

Cedeño E, Cruz A, Cortés J, Melin K, Roman L, Gonzalez A, Duconge J, Santiago D. 

Patient Prefer Adherence. 2022 Jan 11;16:69-78. doi: 10.2147/PPA.S336155. PMID: 35046643; PMCID: PMC8761029.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761029/

Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients. 

Moss LM, Algera MH, Dobbins R, Gray F, Strafford S, Heath A, et al. (2022) 

PLoS ONE 17(1): e0256752. doi.org/10.1371/journal.pone.0256752

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0256752

Buprenorphine Increases HIV-1 Infection In Vitro but Does Not Reactivate HIV-1 from Latency. 

Gornalusse GG, Vojtech LN, Levy CN, Hughes SM, Kim Y, Valdez R, Pandey U, Ochsenbauer C, Astronomo R, McElrath J, Hladik F. 

Viruses. 2021 Jul 27;13(8):1472. doi: 10.3390/v13081472. PMID: 34452338; PMCID: PMC8402857.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402857/

Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. 

Petrakis I, Springer SA, Davis C, Ralevski E, Gu L, Lew R, Hermos J, Nuite M, Gordon AJ, Kosten TR, Nunes EV, Rosenheck R, Saxon AJ, Swift R, Goldberg A, Ringer R, Ferguson R. 

Addict Sci Clin Pract. 2022 Jan 31;17(1):6. doi: 10.1186/s13722-022-00286-6. PMID: 35101115; PMCID: PMC8802273.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802273/

Buprenorphin. Filling the prescription

This article is the first in a series examining the past, present and future of buprenorphine in the treatment of opioid dependence. Buprenorphine is a medication used in opioid substitution treatment (OST), and it has also been used extensively for the management of pain. The surge of buprenorphine prescribing during the COVID-19 pandemic triggered a reflection of its journey, and with the recent introduction of long-acting injectable buprenorphine we question what its future is within drug treatment services. (DDN – Drink and Drug News, UK, Dezember 2021)

https://viewer.joomag.com/ddn-december-2021-december-2021/0873901001638785940/p6?short&

Low- and very low-dose buprenorphine induction: new(ish) uses for an old(ish) medication?. 

Weimer, M.B. and Fiellin, D.A. (2022), 

Addiction. https://doi.org/10.1111/add.15799

https://onlinelibrary.wiley.com/doi/full/10.1111/add.15799

Statement from SAMHSA Leader on FDA’s Drug Safety Alert on Buprenorphine and Risk for Tooth Decay

Today, Miriam Delphin-Rittmon, Ph.D., Assistant Secretary for Mental Health and Substance Use and the leader of the Substance Abuse and Mental Health Services Administration (SAMHSA), released the following statement in response to recent FDA guidance on how to prevent the use of buprenorphine from leading to tooth decay. Buprenorphine and other opioid agonist medications can reduce the saliva production that is important for optimal oral health.

“SAMHSA urges patients and providers to weigh the lifesaving benefits of buprenorphine with this identified risk in making decisions about starting and ongoing use of buprenorphine."

“SAMHSA supports the FDA’s recommendations that simple steps can help reduce the risk of tooth decay in people taking buprenorphine. This includes swishing with water after allowing sublingual and buccal formulations of buprenorphine to completely dissolve and brushing teeth one hour after taking the medication. Other measures can also help maintain healthy teeth and gums, such as twice daily brushing, regular flossing, the regular consumption of water throughout the day, and routine dental checkups.” (Substance Abuse and Mental Health Services Administration (SAMHSA), USA, 13.01.2022)

https://www.samhsa.gov/newsroom/statements/2022/fda-drug-safety-buprenorphine-risk-tooth-decay

  1. Rapid Transition to Buprenorphine in a Patient With Methadone-Related QTc Interval Prolongation. 
  2. Opioid use disorder from poppy seed tea successfully treated with buprenorphine in primary care: a case report. 
  3. Buprenorphine Dosage and Urine Quantitative Buprenorphine, Norbuprenorphine, and Creatinine Levels in an Office-Based Opioid Treatment Program. 
  4. Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients-A Critical Review. 
  5. "I don't want to take buprenorphine for the rest of my life": Acceptance and Commitment Therapy for a Client Struggling to Reduce Low-Dose Buprenorphine (a Hermeneutic Single-Case Efficacy Design).